From the Midwest Rett Syndrome website - It appears that the Gillette Children's Specialty Healthcare (St Paul's Campus) has signed onto the phase III trial??
Gillette Children's participating in Neuren Pharmaceuticals conducting Phase II study of Trofinetide (NNZ-2256) in Rett Syndrome
***** Update (3/12/2018) - Phase III was approved by the FDA and is coming to Gillette soon! *****
https://www.midwestrett.org/news
Release Today Neuren Valuation Estimate Raised, page-79
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |